Loading...
XBRU
BIOS
Market cap1mUSD
May 27, Last price  
0.00EUR
1D
0.00%
1Q
-50.00%
Jan 2017
-99.98%
IPO
-99.99%
Name

Bone Therapeutics SA

Chart & Performance

D1W1MN
P/E
—
P/S
2.04
EPS
—
Div Yield, %
—
Shrs. gr., 5y
78.27%
Rev. gr., 5y
-11.50%
Revenues
543k
+104.14%
0000041,0001,000,00001,000,0001,000,000266,000543,000
Net income
-29m
L+1,310.00%
-3,689,000-4,079,000-5,734,000-14,144,000-12,989,000-12,752,000-14,218,000-10,461,000-11,940,000-12,925,000-2,041,000-28,778,000
CFO
-3m
L+81.68%
-4,050,000-3,274,000-3,524,000-11,765,000-11,369,000-11,018,000-12,901,000-10,400,000-16,082,000-12,784,000-1,910,000-3,470,000

Profile

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
URL
http://www.bonetherapeutics.com/
IPO date
Feb 06, 2015
Employees
20
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
543
104.14%
266
-73.40%
Cost of revenue
7,582
1,709
Unusual Expense (Income)
NOPBT
(7,039)
(1,443)
NOPBT Margin
Operating Taxes
(7)
(1,016)
Tax Rate
NOPAT
(7,032)
(427)
Net income
(28,778)
1,310.00%
(2,041)
-84.21%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,500
(22)
BB yield
-17.89%
0.19%
Debt
Debt current
11,821
5,058
Long-term debt
17,465
17,008
Deferred revenue
Other long-term liabilities
80
71
Net debt
28,759
20,097
Cash flow
Cash from operating activities
(3,470)
(1,910)
CAPEX
(5)
Cash from investing activities
6
1,952
Cash from financing activities
1,735
1,045
FCF
(4,808)
(314)
Balance
Cash
117
1,846
Long term investments
410
123
Excess cash
500
1,956
Stockholders' equity
(28,405)
(1,351)
Invested Capital
33,941
25,380
ROIC
ROCE
EV
Common stock shares outstanding
137,038
120,132
Price
0.06
-36.25%
0.10
-85.59%
Market cap
8,387
-27.28%
11,533
-18.74%
EV
37,353
31,270
EBITDA
(6,796)
(1,383)
EV/EBITDA
Interest
5,954
278
Interest/NOPBT